Research and DevelopmentProduction and Reliability AssurancePartneringPharmaceutical Research and DevelopmentPharmaceutical ManufacturingPharmaceutical SalesMedical Device Research and DevelopmentMedical Device ManufacturingMedical Device Sales
Names without a link are companies not yet registered in OpenBizGraph
§05
Network
NETWORK
Loading the relationship graph...
Drag to move · click to open
§06
History
32 EVENTS
In 1890, Taguchi Santen opened in Osaka Kitahama, marking the start of Santan Pharmaceutical. The flagship product at the time was the cold medicine "Heburin tablets".
The company began in 1890 when Taguchi Kenkichi opened Taguchi Santen. The flagship product at the time was the cold medicine "Heburin tablets".
Founded and launched the cold medicine "Heburin tablet": In 1890, Taguchi Santen opened in Osaka Kitahama, marking the beginning of Santen Pharmaceutical. The flagship product at the time was the cold medicine "Heburin tablet".
Founded in Osaka in 1890, Taguchi Kenkichi opened Taguchi Santen.
In 1899, launched 'Daigaku Eye Drops', using the slogan 'A product of the advancing era, an outstanding eye drop' and the image of university professors as a trademark, quickly spreading throughout Japan.
In 1899, "Daigaku Eye Drops" were launched, and their popularity spread throughout Japan.
Launch of 'Daigaku Eye Drops': During the early Meiji period, many foreign doctors visiting Japan were astonished by the high prevalence of eye diseases among Japanese people, indicating a strong demand for eye drops at that time. At that moment, 'Daigaku Eye Drops' was launched, using a confident slogan 'A product of the advancing era, an outstanding eye drop' and the authoritative image of university professors as a trademark, rapidly spreading throughout Japan.
In 1899, Santen released "Daigaku Eye Drops", the first ophthalmic product.
In 1914, a joint venture company Santen was established, and Manda Tadakuni officially joined as a co-operator.
Established the joint venture Santen: In 1914, the joint venture Santen was established, and Sanda Tadakuni officially joined as a co-operator.
In 1925, Santen Pharmaceutical Co., Ltd. was established, with Manda Tadakuni serving as its first president.
Establishment of San-ten-do Co., Ltd.: Founded in 1925, with Tadakuni Manda as the first president, laying the foundation for San-ten-do Pharmaceutical's development.
In 1935, established the Yodogawa Factory in Higashi-Yodogawa-ku, Osaka City, which became the future headquarters.
Establishment of Yodogawa Factory: Founded in 1935 in Higashi-Yodogawa-ku, Osaka City, becoming the future headquarters.
In 1944, after the air raids of World War II, the main company, the Goryo Bridge factory, the Nakazaki Town factory, and the Sakuragawa factory were all destroyed. The main company relocated to the Yodogawa factory.
Headquarters moved to Yodogawa Factory: In 1944, the headquarters relocated to the Yodogawa factory.
In 1945, it was renamed Santen Pharmaceutical Co., Ltd.
Renamed to Santen Pharmaceutical Co., Ltd.: In 1945, the company was renamed Santen Pharmaceutical Co., Ltd.
In 1952 (Showa 27), the company reorganized its business focus around ophthalmic drugs.
Reorganized business focus around ophthalmic drugs: In 1952, the company reorganized its business content with a focus on eye medicine.
Entered the medical drug market: In 1958, the company entered the medical drug market and officially renamed itself Santen Pharmaceutical Co., Ltd.
Released Japan's first eye drops using a plastic container, 'Super Sante': Released in 1962.
Released self-developed product 'Thiola': Released in 1963.
Released 'Sante De U' eye drops: Released in 1965.
Launch of "Ecolicin" eye drops, launch of "Kari Uni" eye drops, completion of Nara R&D Center and Shiga Factory, launch of "Cravit" eye drops, introduction of new container type "Dimple Bottle", launch of "Sante De U Plus E α" eye drops, "Sante 40" eye drops, "Sante 40V" eye drops, acquisition of French company Novagali Pharma S.A. (subsidiary), launch of "Elyea" vitreous injection, launch of "Sante Medical Guard" eye drops, "Sante 40 Series" eye drops, launch of "TAPROS MINI" eye drops, launch of "Alesion" eye drops, launch of artificial lens "Eternity Natural Uni", launch of "Sante Beauteye" eye drops, "Sante PC" eye drops, "Sante Quick Drop 40" eye drops, "Sante ALn" eye drops.
In 1990, a long-term vision was announced. With a focus on vision and health, the company pledged to contribute to society with the best products and services, entering a new stage of growth.
In 1990, the company expanded its product lineup, achieved growth in Japan, completed the Shiga factory, and entered the European market.
In 1990, the company entered the European market and focused on proactive business development to contribute to patients worldwide.
In 1990, we worked on building our business foundation in Asia by selling our products in China, completing the Suzhou factory, and establishing a base in South Korea.
In 1990, marking its 100th anniversary, the company announced a long-term vision, expanded its product lineup, completed the Shiga factory, and entered the European market.
In 2014 (Heisei 26), acquired eye drop products from the American Merck pharmaceutical company, established subsidiaries in Switzerland, Italy, the United Kingdom, Spain, Thailand, Malaysia, and the Philippines, and launched 'TAPCOM' eye drops and 'Soft Santear Hitomi Stretch' eye drops.
Acquired eye drop products from the American Merck pharmaceutical company, established subsidiaries in Switzerland, Italy, the United Kingdom, Spain, Thailand, Malaysia, and the Philippines, launched 'TAPCOM' eye drops, launched 'Soft Santear Hitomi Stretch' eye drops, acquired the American company InnFocus, launched 'Sante Medical 12' eye drops, 'Sante Medical Guard EX' eye drops, 'Sante Medical Active' eye drops, released artificial intraocular lens 'Eternity Natural Unir', and launched 'Sante Beauteye Contact' eye drops.
§07
News
57 ARTICLES
Stereoscopic Eye Drop for Myopia Progression Suppression Receives Approval in South Korea
Santen Pharmaceutical has obtained approval for the sale of the eye drop STN1012700 (Ryjusea 0.25mg/mL eye drop) in South Korea, aimed at suppressing the progression of myopia. This is the second approval in Santen’s Asian business region, following the Philippines. The drug has been available for sale in Japan since April 2025, and its efficacy is based on the results of Phase II/III trials conducted in Japan.
Price Revision of Some OTC Drugs
Sentan Pharmaceutical announced that it will revise the shipping price and manufacturer suggested retail price for 18 OTC drugs due to increases in raw material, packaging material, energy, and logistics costs. The manufacturer suggested retail price is a reference price; the actual in-store selling price is determined by each retailer.
The Japanese and English versions of the 2026 March fiscal year integrated report have been issued. Based on the medium-term management plan, it outlines the future of ophthalmic care, introduces strategies for addressing unmet needs and sustainable growth, and is available on the corporate website.
Santen Pharmaceutical Transfers All Shares of AVS to SpyGlass
Santen Pharmaceutical transferred all shares of its subsidiary, Advanced Vision Science, to SpyGlass Pharma. As a result, AVS will continue to manufacture and supply IOL products, and Santen will continue its IOL business in Japan.
China accepts new drug application for Santen's STN1012700
Santen Pharmaceutical announced that China's Center for Drug Evaluation (CDE) accepted for review a new drug application for STN1012700 (atropine sulfate ophthalmic solution 0.025%). In Japan, it has been sold as RYJUSEA® since April 2025.
Santen receives acceptance of application for myopia-control eye drops in China
Santen Pharmaceutical announced that China's application for approval of STN1012700 eye drops, intended to slow the progression of myopia, has been accepted. The single-use drops, containing atropine sulfate hydrate, have been sold in Japan since April 2025. Myopia among children and adolescents is a public health concern in China, and the product is moving toward potential approval.
Santen Launches Rhopressa® in Japan for Glaucoma
Santen Pharmaceutical launched Rhopressa® ophthalmic solution 0.02% in Japan on August 17, 2026, for the treatment of glaucoma and ocular hypertension. The product contains the active ingredient netarsudil mesylate and is intended to lower intraocular pressure.
Santen Launches Rhopressa 0.02% Eye Drops for Glaucoma and Ocular Hypertension
On August 17, 2026, Santen launched Rhopressa 0.02% eye drops in Japan for glaucoma and ocular hypertension. Once-daily dosing can effectively lower intraocular pressure, offering a new option for patients who have not responded adequately to existing treatments. Its active ingredient, netarsudil mesylate, promotes aqueous humor outflow and reduces its production.
Santen Holds Press Seminar on Ptosis
Santen held a seminar on the realities, challenges, and current treatment of ptosis. Dr. Mika Tanabe of Kyushu University discussed the condition, its causes, the estimated number of undiagnosed patients, and how a new eye-drop treatment may expand options. Ptosis can affect daily life, underscoring the importance of information and public awareness.
Santen Pharmaceutical Donates 10 Million Yen in Aid for Kumamoto Earthquake
Santen Pharmaceutical Co., Ltd. has donated 10 million yen in aid through the Japanese Red Cross Society to support victims and recovery from the Kumamoto Earthquake in Reiwa 8. The company also implements a matching gift program where employees' donations are matched by the company. We pray for the early recovery and reconstruction of the affected areas.
§08
Public records
GOV
National Tax Agency basic information5120001051819
Source: National Tax Agency Corporate Number Publication Site, basic three items
Trade name
参天製薬株式会社
Trade name (kana)
サンテンセイヤク
Name in English
Corporation type
301
Address
〒530-0011 大阪府大阪市北区大深町4番20号
Postal code
5300011
Prefecture code
27
City code
127
Address outside Japan
Prefecture in English
City in English
Address outside Japan in English
Corporate number assignment date
2015-10-05
Update date
2020-01-17
Change date
2020-01-15
Registry closure date
Reason for registry closure
Successor corporate number
Details of the change
Latest record
1
Excluded from search
0
Processing type
12
Correction type
0
Trade name image ID
Address image ID
Sequence number
4199900
METI gBizINFO5120001051819
Source: gBizINFO (Ministry of Economy, Trade and Industry)